XYLOCAINE 2% INJ (5ML POLYAMP)

Šalis: Malaizija

kalba: anglų

Šaltinis: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Veiklioji medžiaga:

LIGNOCAINE HCL/LIDOCAINE HCL

Prieinama:

Aspen Medical Products Malaysia Sdn Bhd

INN (Tarptautinis Pavadinimas):

LIGNOCAINE HCL/LIDOCAINE HCL

Vienetai pakuotėje:

5cubic inch50Units CUBIC INCH

Pagaminta:

ASTRAZENECA PTY LTD

Prekės savybės

Xylocaine Product Information 1
Xylocaine 2% Injection
Lignocaine Hydrochloride
PRODUCT INFORMATION
Injection solutions for the production of local or regional anaesthesia NAME OF DRUG
The active ingredient in XYLOCAINE is lignocaine hydrochloride.
The CAS number for lignocaine hydrochloride (AAN) is 6108 -05- 0 and lignocaine hydrochloride
anhydrous is 73 -78 -9.
The chemical name for lignocaine hydrochloride is 2 -Diethylaminoaceto -2’6’ -xylidide.
The Australian Approved Name is lignocaine hydrochloride. The chemical structure of lignocaine is:
CH 3
NHCOCH 2N(C 2H5)2
CH 3
DESCRIPTION
Lignocaine is classed as a membrane stabilising agent and is a local anaesthetic of the amide type. It
is extremely stable and plain solutions can be sterilised by autoclaving, repeated a maximum of two
times if necessary.
Plain aqueous solutions are sterile, isotonic and contain lignocaine hydrochloride, sodium chloride,
sodium hydroxide for pH adjustment and water for injections. XYLOCAINE solutions contain no
an timicrobial agent and should be used only once and any residue discarded.
Plain aqueous solutions of lignocaine hydrochloride have a pH of 5.0 - 7.0 (approx.). Lignocaine base
has a pKa of 7.85 (25 °
C), an oil/water coefficient of 2.9 and a molecular weigh t of 234.3.
PHARMACOLOGY
Lignocaine, like other local anaesthetics, causes a reversible blockade of impulse propagation along
nerve fibres by preventing the inward movement of sodium ions through the nerve membrane.
Local anaesthetics of the amide type are thought to act within the sodium channels of the nerve
membrane. Local anaesthetic drugs may have similar effects on excitable membranes in the brain and
myocardium. If excessive amoun ts of drug reach the systemic circulation rapidly, symptoms and signs
of toxicity will appear, emanating mainly from the central nervous system and cardiovascular
systems.